CN Stock MarketDetailed Quotes

002294 Shenzhen Salubris Pharmaceuticals

Watchlist

33.97
-0.21-0.61%

Market Closed Dec 13 15:00 CST

37.87BMarket Cap61.99P/E (TTM)

Shenzhen Salubris Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Shenzhen Salubris Pharmaceuticals Q3 2024 Earnings Date

Currency：CNYOct 22, 2024

	Estimate (YoY)	Actual (YoY)	Vs Estimate (% Chg)
Revenue	--	958.43M	--
		+24.15%
EPS	0.13	0.15	+0.02
Beat Est.	0.00%	+15.38%	+15.38%

Analyst Rating

Strong Buy

Dec 14, 2024

Shenzhen Salubris Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CNY

Actual

Estimate

Date	Period	Revenue/Estimate	Earnings Call
Oct 29, 2019	2019/Q3	1.208B / 1.278B	--
Aug 27, 2019	2019/Q2	1.168B / 1.229B	--
Apr 23, 2019	2019/Q1	1.189B / 1.229B	--

DatePeriodRevenue/EstimateEarnings Call

Oct 29, 20192019/Q31.208B / 1.278B--

Aug 27, 20192019/Q21.168B / 1.229B--

Apr 23, 20192019/Q11.189B / 1.229B--

--------

Unlock Free Earnings Estimates

Open Account

Shenzhen Salubris Pharmaceuticals Earnings Reports

Xinlitai: Report for the third quarter of 2024

Oct 21 12:00 ET

Xinlitai: 2024 Semi-Annual Report Summary

Aug 26 12:00 ET

Xinlitai: 2024 Semi-Annual Report

Aug 26 12:00 ET

Xinlitai: First Quarter Report 2024

Apr 22 12:00 ET

Symbol Price % Chg

Zhejiang Zoenn Design

300901

14.86 +20.03%

Zhejiang Meorient Commerce & Exhibition Inc.

300795

22.36 +20.02%

Fujian Zitian Media Technology

300280

22.18 +20.02%

Zhejiang Prulde Electric Appliance

301353

36.46 +20.01%

See the daily top gainer.

Analysis

Analyst Rating

Updated: Dec 14, 2024

Strong Buy

Strong Buy
81.25%
Buy
18.75%
Hold
0.00%
Underperform
0.00%
Sell
0.00%

Price Target

No Data

Investment Theme

Monoclonal Antibody Concept

Intraday-1.90%